Navigation Links
Newly discovered protein an important tool for sleeping sickness research

ize that base J (beta-D-glucosylhydroxymethyluracil) may play an important role in the gene silencing process behind antigenic variation. With the goal of learning how the organism regulates the process of antigenic variation, the scientists have been trying to understand how the trypanosome makes base J.

The discovery of JBP2, a member of a protein family that helps control DNA-related functions, is a significant breakthrough in this quest because Sabatini and his colleagues were able to demonstrate that the protein is the key regulator of base J synthesis. This will provide the scientists a new tool to elucidate the biological function of this unique modified DNA base in the regulation of antigenic variation.

If base J does indeed play a role in the gene silencing that enables the trypanosome to change its antigen coating, the discovery of JBP2 may one day enable scientists to create a drug that prevents the manufacture of base J, affecting the trypanosome's ability to vary its antigenic coating, and therefore allowing the human immune system to kill it.

Understanding trypanosomes at the molecular level is key to fighting African sleeping sickness and diseases caused by similar parasites.


'"/>

Source:Marine Biological Laboratory


Page: 1 2

Related biology news :

1. Newly-discovered class of genes determines ?and restricts ?stem cell fate
2. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
3. Newly Discovered Compound Blocks Known Cancer-Causing Protein
4. Newly discovered pathway might help in design of cancer drugs
5. Newly Discovered Branding Process Helps Immune System Cells Pick Their Fights
6. Newly discovered genetic disease sheds light on bodys water balance
7. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
8. Newly recognized gene mutation may reduce seeds, resurrect plants
9. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
10. Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool
11. Newly identified mechanism helps explain why people of African descent are more vulnerable to TB
Post Your Comments:
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
(Date:7/10/2014)...  Unisys Corporation,s (NYSE: UIS ) subsidiary in ... announced that it has been selected by the Dutch Custodial ... Basic Provision Biometrics solution for penitentiaries across The ... with a solution based on its open standards-based LEIDA ... contract is up to seven years, with the new system ...
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... in his thesis that streams and lakes of Northern Sweden ... the atmosphere. Erik defends his findings at Sweden,s Ume University ... this study accounted for only about four percent of the ... releasing about ten times as much carbon as lakes," says ...
... and Drug Administration (FDA) mandates adequate enrollment of women in ... sex differences in device safety and effectiveness are not overlooked. ... of a study evaluating the participation of women and analysis ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers ...
... developed efficiency in the biomass supply and use for ... Energy and Environment Partnership Programme of the Ministry for ... working phases reduce transport costs by 15%. The production ... demonstrated to be financially and technologically sound. , Vietnam ...
Cached Biology News:Arctic inland waters emit large amounts of carbon 2Biomass supply chains developed by VTT speed up use of bioenergy in Vietnam 2
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... Capital, a firm specializing in acquiring and managing food ... the Slim-Fast brand from Unilever. Unilever will retain a ... were not disclosed. Slim-Fast is a branded ... shakes, powders, bars and snacks to retail customers throughout ... United Kingdom and Ireland.  The ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
... of Hepatitis C Patients Is Skewed Towards Medicare ... in the General Population, According to a New ... Decision Resources, one of the world,s leading ... healthcare issues, finds that hepatitis C virus patient ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) announced ... for the Riquent(R) Phase 3 ASPEN trial, the ... of the trial is,futile. BioMarin and partner ... unblind the data and evaluate all of the ...
Cached Biology Technology:SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3